Pfizer Commits $650M Upfront in $10.5B Oncology Collaboration with Innovent for 12 New Medicines
PFE is trading near its 52-week low of $23.06 (13% above the low).
Summary
Pfizer has entered a global strategic collaboration with Innovent Biologics to develop 12 early-stage oncology medicines, including novel antibody-drug conjugates and multi-specific antibodies. Pfizer will make a $650 million upfront payment to Innovent and is eligible for up to $9.85 billion in development, regulatory, and commercial milestone payments, totaling up to $10.5 billion. This significant partnership strengthens Pfizer's oncology pipeline by leveraging Innovent's early-stage innovation and Pfizer's global development and commercialization capabilities. This follows a period of positive news for Pfizer, including strong Q1 results and an acquisition of obesity assets, further bolstering its long-term growth prospects in a critical therapeutic area.
At the time of this announcement, PFE was trading at $26.13 on NYSE in the Life Sciences sector, with a market capitalization of approximately $149B. The 52-week trading range was $23.06 to $28.75. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: PR Newswire.